The Elusive Road Towards Effective Cancer Prevention and Treatment - Franklyn De Silva, Jane Alcorn

The Elusive Road Towards Effective Cancer Prevention and Treatment

Buch | Hardcover
216 Seiten
2022
CRC Press (Verlag)
978-1-032-35130-8 (ISBN)
119,95 inkl. MwSt
Our understanding of cancer has expanded in multiple directions including pathophysiological, biochemical, toxicological, and pharmacological aspects. Collectively, these areas will strengthen the ability to harness the greater benefit of oncology research to improve patient survival and quality of life and this is illustrated in this volume.
Cancer will remain a global major health problem unless new diagnostic, prognostic, and management approaches are discovered to address both loss of life and quality of life. Here we summarize the general physiology, pathology, heterogeneity, and evolution of cancer, current status, limitations and challenges associated with prevention, incidence, treatment, survival, and mortality, as well as future directions with regards to solid tumors. Perspectives are provided on how to improve pre-clinical understandings, outcomes, and patient care. Further, this comprehensive, timely overview of the literature has educational value as part of an academic course, seminar, or as a supplementary text.

Features :



This book summarizes the current status, successes, difficulties, advancements, limitations, and challenges in medical interventions that impact patients’ quality of life.



Includes concise descriptions of all relevant cell and molecular biology concepts including evolutionary paradigms, hallmarks of cancer, and heterogeneity to help understand the pathophysiology of cancer, cancer-associated disease conditions, and effective cancer therapy.



Contains an array of colorful figures and schematics summarizing complex informative pathological, physiological, and biochemical concepts.



Covers a multitude of sub-topics pertaining to cancer biology including diagnosis; chemotherapy, radiotherapy and targeted therapy; metastasis; disseminated and circulating tumor cells, and cancer stem cells; drug resistance and cellular reprogramming; complex epigenetics; tumor-derived exosomes; oncogenic viruses; metabolic syndrome and cancer metabolism; convoluted neovascularization; efficient biomarkers; immunotherapy; role of nutraceuticals and natural products.



Provides perspectives on how to improve pre-clinical understandings, and outcomes, linking toxicological, and pharmacological aspects in patient care.



This timely, relevant comprehensive assortment of scientific literature has educational value to a wider audience including as part of an academic course, seminar, or as a supplementary text.

Franklyn De Silva - S. F. De Silva is a Ph.D. candidate in Pharmacy/ Pharmaceutical Sciences (completion 2022) enrolled in the College of Graduate and Postdoctoral Studies, and the College of Pharmacy and Nutrition, at the University of Saskatchewan, Canada. He is a member of the Drug Discovery and Development Research Group. Franklyn has an AS in Biotechnology from Ellsworth College, Iowa, USA; a BS (double major: Biotechnology and Chemistry, minor in Biology) and MS (Biology: Cell Biology and Molecular Pharmacology) from West Texas A & M University, USA; and completed a biomedical research internship at Texas Tech University Health Sciences Center, USA. He has worked in the USA and Canada as a biomedical research scientist in areas involving cell & molecular biology, medicinal chemistry, pharmaco-kinetics/dynamics, xenobiotics, nutrient transporters, cellular metabolism, small molecule drugs, natural products, and nutraceuticals. Jane Alcorn - J. Alcorn is Dean and Professor of the College of Pharmacy and Nutrition, University of Saskatchewan. She has a Doctor of Veterinary Medicine from the Western College of Veterinary Medicine, University of Saskatchewan, and a Ph.D. in Pharmaceutical Sciences (Pharmacokinetics) from the University of Kentucky. Jane Alcorn is a member of the Drug Discovery and Development Research Group and the Cannabinoid Research Initiative of Saskatchewan. Jane’s expertise in pharmacokinetics has been applied to numerous collaborative research projects involving cancer and the health benefits of phytochemicals such as flaxseed lignans and the cannabinoids.

Overview and Current Status of Cancer; Introduction; Incidence, Mortality, and Prevention; Diagnosis and Pathobiology; Introduction; Diagnosis; Evolutionary Paradigms and Origin of Cancer; Heterogeneity and Dynamics of Cancer; Hallmarks of Cancer; Molecular Biology of Carcinogenesis; Genetic Underpinnings; Epigenetic Underpinnings; Characteristics, Events, and Stages in Tumorigenesis; Introduction; Metastases and the Microenvironment; Cell-of-Origin, Disseminated and Circulating Tumor Cells, and Cancer Stem Cells;Tumor-derived Exosomes and Particles; Oncogenic Viruses;Metabolic Syndrome and Cancer Metabolism; Convoluted Neovascularization; Treatments and Challenges; Introduction; Chemotherapy, Radiotherapy, and Targeted Therapy; Immunotherapy; Drug Resistance and Cellular Reprogramming; Efficient Biomarkers; The Role of Nutraceuticals and Natural Products; Physiologically Relevant Nutrikinetics and Nutridynamics; Additional Remarks, Perspectives, and Conclusions; References

Erscheinungsdatum
Zusatzinfo 5 Tables, black and white; 21 Line drawings, black and white; 21 Illustrations, black and white
Verlagsort London
Sprache englisch
Maße 156 x 234 mm
Gewicht 439 g
Themenwelt Medizin / Pharmazie Allgemeines / Lexika
Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Naturwissenschaften Biologie
ISBN-10 1-032-35130-6 / 1032351306
ISBN-13 978-1-032-35130-8 / 9781032351308
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Hannes Leischner

Buch | Softcover (2023)
Urban & Fischer in Elsevier (Verlag)
27,00
Resilienz innovativ stärken : ein Praxishandbuch

von Christa Diegelmann; Margarete Isermann; Tanja Zimmermann

Buch | Softcover (2023)
Kohlhammer (Verlag)
36,00